Trial Profile
Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2020
Price :
$35
*
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors GlycoMimetics
- 26 Nov 2013 New trial record